Stanford trial points to a new CAR-T drug, spotlighting a fresh target for next-gen cell therapies – Endpoints News
Endpoints News |
Stanford trial points to a new CAR–T drug, spotlighting a fresh target for next-gen cell therapies
Endpoints News CAR–T researchers have had years to study CD19 protein molecules as a target in their successful leukemia studies. But a small, exploratory study at Stanford underscores that there's substantial promise in expanding their scope to include CD22 … New potential treatment for leukemia found US Scientists find new possible cure for leukemia |
